JP2003514821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514821A5 JP2003514821A5 JP2001538914A JP2001538914A JP2003514821A5 JP 2003514821 A5 JP2003514821 A5 JP 2003514821A5 JP 2001538914 A JP2001538914 A JP 2001538914A JP 2001538914 A JP2001538914 A JP 2001538914A JP 2003514821 A5 JP2003514821 A5 JP 2003514821A5
- Authority
- JP
- Japan
- Prior art keywords
- diseases
- formula
- physiologically acceptable
- hal
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 206010006451 Bronchitis Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000007451 Chronic Bronchitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 206010027175 Memory impairment Diseases 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- 208000006641 Skin Disease Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- -1 imidazole compound Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Description
【請求項1】
式I
【化1】
(式中、
R1およびR2は、それぞれ互いに独立して、A1、OA1、SA1またはHalを示し、
A1は、H、A、アルケニル、シクロアルキルまたはアルキレンシクロアルキルを示し、
Aは、1〜10個の炭素原子を有するアルキルを示し、
Halは、F、Cl、BrまたはIを示し、そして
Xは、O、S、SOまたはSO2を示す)
のイミダゾール化合物、あるいはそれらの生理学的に許容し得る塩および/または溶媒和物。
式I
【化1】
(式中、
R1およびR2は、それぞれ互いに独立して、A1、OA1、SA1またはHalを示し、
A1は、H、A、アルケニル、シクロアルキルまたはアルキレンシクロアルキルを示し、
Aは、1〜10個の炭素原子を有するアルキルを示し、
Halは、F、Cl、BrまたはIを示し、そして
Xは、O、S、SOまたはSO2を示す)
のイミダゾール化合物、あるいはそれらの生理学的に許容し得る塩および/または溶媒和物。
【請求項2】
医薬としての、請求項1に記載の式Iのイミダゾール化合物、あるいはそれらの生理学的に許容し得る塩および/または溶媒和物。
医薬としての、請求項1に記載の式Iのイミダゾール化合物、あるいはそれらの生理学的に許容し得る塩および/または溶媒和物。
【請求項4】
アレルギー性疾患、喘息、慢性気管支炎、アトピー性皮膚炎、乾癬またはその他の皮膚疾患、炎症性疾患、例えばリウマチ様関節炎などの自己免疫疾患、多発性硬化症、クローン病、糖尿病または潰瘍性大腸炎、骨粗鬆症、移植拒絶反応、悪液質、腫瘍増殖または腫瘍転移、敗血症、記憶障害、アテローム性動脈硬化症、あるいはエイズに対抗するための、請求項3に記載の医薬。
アレルギー性疾患、喘息、慢性気管支炎、アトピー性皮膚炎、乾癬またはその他の皮膚疾患、炎症性疾患、例えばリウマチ様関節炎などの自己免疫疾患、多発性硬化症、クローン病、糖尿病または潰瘍性大腸炎、骨粗鬆症、移植拒絶反応、悪液質、腫瘍増殖または腫瘍転移、敗血症、記憶障害、アテローム性動脈硬化症、あるいはエイズに対抗するための、請求項3に記載の医薬。
【請求項6】
アレルギー性疾患、喘息、慢性気管支炎、アトピー性皮膚炎、乾癬またはその他の皮膚疾患、炎症性疾患、例えばリウマチ様関節炎などの自己免疫疾患、多発性硬化症、クローン病、糖尿病または潰瘍性大腸炎、骨粗鬆症、移植拒絶反応、悪液質、腫瘍増殖または腫瘍転移、敗血症、記憶障害、アテローム性動脈硬化症、あるいはエイズに対抗するための医薬の製造のための、請求項1に記載の式Iの化合物および/またはそれらの生理学的に許容し得る塩もしくは溶媒和物の使用。
アレルギー性疾患、喘息、慢性気管支炎、アトピー性皮膚炎、乾癬またはその他の皮膚疾患、炎症性疾患、例えばリウマチ様関節炎などの自己免疫疾患、多発性硬化症、クローン病、糖尿病または潰瘍性大腸炎、骨粗鬆症、移植拒絶反応、悪液質、腫瘍増殖または腫瘍転移、敗血症、記憶障害、アテローム性動脈硬化症、あるいはエイズに対抗するための医薬の製造のための、請求項1に記載の式Iの化合物および/またはそれらの生理学的に許容し得る塩もしくは溶媒和物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19954707.6 | 1999-11-13 | ||
DE19954707A DE19954707A1 (de) | 1999-11-13 | 1999-11-13 | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
PCT/EP2000/010765 WO2001036425A2 (de) | 1999-11-13 | 2000-10-31 | Imidazolverbindungen als phosphodiesterase vii-hemmer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2003514821A JP2003514821A (ja) | 2003-04-22 |
JP2003514821A5 true JP2003514821A5 (ja) | 2007-12-20 |
JP4819272B2 JP4819272B2 (ja) | 2011-11-24 |
Family
ID=7928973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001538914A Expired - Fee Related JP4819272B2 (ja) | 1999-11-13 | 2000-10-31 | ホスホジエステラーゼvii阻害剤として用いられるイミダゾール化合物 |
Country Status (23)
Country | Link |
---|---|
US (1) | US6884800B1 (ja) |
EP (1) | EP1228073B1 (ja) |
JP (1) | JP4819272B2 (ja) |
KR (1) | KR20020049051A (ja) |
CN (1) | CN1390222A (ja) |
AR (1) | AR026421A1 (ja) |
AT (1) | ATE245653T1 (ja) |
AU (1) | AU775886B2 (ja) |
BR (1) | BR0015487A (ja) |
CA (1) | CA2391087A1 (ja) |
CZ (1) | CZ20021474A3 (ja) |
DE (2) | DE19954707A1 (ja) |
DK (1) | DK1228073T3 (ja) |
ES (1) | ES2200968T3 (ja) |
HU (1) | HUP0203422A3 (ja) |
MX (1) | MXPA02004728A (ja) |
NO (1) | NO20022232L (ja) |
PL (1) | PL355098A1 (ja) |
PT (1) | PT1228073E (ja) |
RU (1) | RU2002113759A (ja) |
SK (1) | SK6012002A3 (ja) |
WO (1) | WO2001036425A2 (ja) |
ZA (1) | ZA200204729B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
BRPI0809244A2 (pt) * | 2007-03-27 | 2014-09-23 | Omeros Corp | Métodos de tratamento de uma anormalidade de movimento, e para identificação de um agente que inibe a atividade pde7. |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
DE102007047738A1 (de) * | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
US20120115849A1 (en) | 2010-11-08 | 2012-05-10 | Demopulos Gregory A | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP3652180B1 (en) | 2017-07-12 | 2023-11-29 | Dart NeuroScience, LLC | Substituted benzoxazole and benzofuran compounds as pde7 inhibitors |
WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2919271A (en) * | 1957-12-05 | 1959-12-29 | Smith Kline French Lab | 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines |
CA2051697C (en) * | 1989-06-09 | 1996-10-08 | Malcolm Wilson Moon | Heterocyclic amines having central nervous system activity |
US5318965A (en) * | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
-
1999
- 1999-11-13 DE DE19954707A patent/DE19954707A1/de not_active Withdrawn
-
2000
- 2000-10-31 PL PL00355098A patent/PL355098A1/xx unknown
- 2000-10-31 CZ CZ20021474A patent/CZ20021474A3/cs unknown
- 2000-10-31 AT AT00975978T patent/ATE245653T1/de not_active IP Right Cessation
- 2000-10-31 WO PCT/EP2000/010765 patent/WO2001036425A2/de not_active Application Discontinuation
- 2000-10-31 JP JP2001538914A patent/JP4819272B2/ja not_active Expired - Fee Related
- 2000-10-31 KR KR1020027006131A patent/KR20020049051A/ko not_active Application Discontinuation
- 2000-10-31 SK SK601-2002A patent/SK6012002A3/sk unknown
- 2000-10-31 PT PT00975978T patent/PT1228073E/pt unknown
- 2000-10-31 ES ES00975978T patent/ES2200968T3/es not_active Expired - Lifetime
- 2000-10-31 HU HU0203422A patent/HUP0203422A3/hu unknown
- 2000-10-31 CN CN00815534A patent/CN1390222A/zh active Pending
- 2000-10-31 MX MXPA02004728A patent/MXPA02004728A/es not_active Application Discontinuation
- 2000-10-31 BR BR0015487-3A patent/BR0015487A/pt not_active Application Discontinuation
- 2000-10-31 RU RU2002113759/04A patent/RU2002113759A/ru unknown
- 2000-10-31 AU AU13907/01A patent/AU775886B2/en not_active Ceased
- 2000-10-31 US US10/129,629 patent/US6884800B1/en not_active Expired - Fee Related
- 2000-10-31 CA CA002391087A patent/CA2391087A1/en not_active Abandoned
- 2000-10-31 EP EP00975978A patent/EP1228073B1/de not_active Expired - Lifetime
- 2000-10-31 DE DE50003036T patent/DE50003036D1/de not_active Expired - Lifetime
- 2000-10-31 DK DK00975978T patent/DK1228073T3/da active
- 2000-11-10 AR ARP000105929A patent/AR026421A1/es unknown
-
2002
- 2002-05-10 NO NO20022232A patent/NO20022232L/no not_active Application Discontinuation
- 2002-06-12 ZA ZA200204729A patent/ZA200204729B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003514821A5 (ja) | ||
RU2002113750A (ru) | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII | |
JP2019104748A5 (ja) | ||
JP2003531118A5 (ja) | ||
JP2020183410A5 (ja) | ||
JP2007510619A5 (ja) | ||
JP2005508349A5 (ja) | ||
JP2015502387A5 (ja) | ||
JP2010530881A5 (ja) | ||
CA2540163A1 (en) | Thrombin receptor antagonists | |
JP2003500464A5 (ja) | ||
JP2005525294A5 (ja) | ||
JP2003534325A5 (ja) | ||
JP2012510502A5 (ja) | ||
JP2008520662A5 (ja) | ||
JP2005520923A5 (ja) | ||
ZA200508622B (en) | Pesticidal (dihalopropenyl) phenylalkyl substituted benzoxazole and benzothiazole derivatives | |
JP2005508972A5 (ja) | ||
JP2008509896A (ja) | 保護化アミノチアゾールのフッ素化方法 | |
JP2006526608A5 (ja) | ||
RU2002113759A (ru) | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII | |
JP2008543821A5 (ja) | ||
JP2008509210A5 (ja) | ||
JP2004510813A5 (ja) | ||
JP2003508534A5 (ja) |